Coherus BioSciences Stock Forecast, Price & News

Coherus BioSciences (NASDAQ:CHRS) Frequently Asked Questions

Is Coherus BioSciences a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Coherus BioSciences in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Coherus BioSciences stock.
View analyst ratings for Coherus BioSciences or view top-rated stocks.

How has Coherus BioSciences' stock been impacted by COVID-19?

Coherus BioSciences' stock was trading at $15.87 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CHRS stock has increased by 12.5% and is now trading at $17.86.
View which stocks have been most impacted by COVID-19.

When is Coherus BioSciences' next earnings date?

Coherus BioSciences is scheduled to release its next quarterly earnings announcement on Wednesday, February 23rd 2022.
View our earnings forecast for Coherus BioSciences.

How were Coherus BioSciences' earnings last quarter?

Coherus BioSciences, Inc. (NASDAQ:CHRS) issued its earnings results on Sunday, November, 7th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by $0.12. The biotechnology company had revenue of $82.50 million for the quarter, compared to analyst estimates of $86.96 million. Coherus BioSciences had a negative net margin of 63.72% and a negative trailing twelve-month return on equity of 133.21%. During the same period last year, the firm posted $0.33 earnings per share.
View Coherus BioSciences' earnings history.

What price target have analysts set for CHRS?

3 brokers have issued 12-month target prices for Coherus BioSciences' shares. Their forecasts range from $22.00 to $30.00. On average, they anticipate Coherus BioSciences' share price to reach $25.75 in the next twelve months. This suggests a possible upside of 44.2% from the stock's current price.
View analysts' price targets for Coherus BioSciences or view top-rated stocks among Wall Street analysts.

Who are Coherus BioSciences' key executives?

Coherus BioSciences' management team includes the following people:

• Denny M. Lanfear, Chairman, President & Chief Executive Officer (LinkedIn Profile)
• Vincent R. Anicetti, Chief Operating Officer
• McDavid Stilwell, Chief Financial Officer (LinkedIn Profile)
• Barbara K. Finck, Chief Medical Officer
• Vladimir Vexler, Chief Scientific Officer (LinkedIn Profile)

What is Dennis M. Lanfear's approval rating as Coherus BioSciences' CEO?

21 employees have rated Coherus BioSciences CEO Dennis M. Lanfear on Glassdoor.com. Dennis M. Lanfear has an approval rating of 95% among Coherus BioSciences' employees. This puts Dennis M. Lanfear in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Coherus BioSciences' key competitors?

Some companies that are related to Coherus BioSciences include Denali Therapeutics (DNLI), Exelixis (EXEL), Abcam (ABCM), Adagio Therapeutics (ADGI), Fate Therapeutics (FATE), Beam Therapeutics (BEAM), Kodiak Sciences (KOD), Halozyme Therapeutics (HALO), Twist Bioscience (TWST), Ablynx (ABLYF), Adaptive Biotechnologies (ADPT), SpringWorks Therapeutics (SWTX), Sana Biotechnology (SANA), Valneva (VALN) and Bavarian Nordic A/S (BVNRY).
View all of CHRS's competitors.

What other stocks do shareholders of Coherus BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Coherus BioSciences investors own include Halozyme Therapeutics (HALO), Chembio Diagnostics (CEMI), Exelixis (EXEL), Heron Therapeutics (HRTX), TG Therapeutics (TGTX), Intelsat (I), Idera Pharmaceuticals (IDRA), Immunomedics (IMMU), Sangamo Therapeutics (SGMO) and Viking Therapeutics (VKTX).

What is Coherus BioSciences' stock symbol?

Coherus BioSciences trades on the NASDAQ under the ticker symbol "CHRS."

Who are Coherus BioSciences' major shareholders?

Coherus BioSciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (15.15%), Alliancebernstein L.P. (6.00%), Geode Capital Management LLC (1.57%), C WorldWide Group Holding A S (1.21%), Peregrine Capital Management LLC (1.15%) and Bank of New York Mellon Corp (1.06%). Company insiders that own Coherus BioSciences stock include Dennis M Lanfear, James Healy, Jean-Frederic Viret, Mary T Szela, Mats Wahlstrom, Mcdavid Stilwell, Vincent R Anicetti and Vladimir Vexler.
View institutional ownership trends for Coherus BioSciences.

Which major investors are selling Coherus BioSciences stock?

CHRS stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Jupiter Asset Management Ltd., Citigroup Inc., Thompson Siegel & Walmsley LLC, Morgan Stanley, Peregrine Capital Management LLC, C WorldWide Group Holding A S, and Eagle Asset Management Inc.. Company insiders that have sold Coherus BioSciences company stock in the last year include Dennis M Lanfear, James Healy, Jean-Frederic Viret, Mcdavid Stilwell, Vincent R Anicetti, and Vladimir Vexler.
View insider buying and selling activity for Coherus BioSciences or view top insider-selling stocks.

Which major investors are buying Coherus BioSciences stock?

CHRS stock was acquired by a variety of institutional investors in the last quarter, including Suvretta Capital Management LLC, Nordea Investment Management AB, Phocas Financial Corp., Millennium Management LLC, Credit Suisse AG, SG Americas Securities LLC, Alliancebernstein L.P., and UBS Group AG.
View insider buying and selling activity for Coherus BioSciences or or view top insider-buying stocks.

How do I buy shares of Coherus BioSciences?

Shares of CHRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Coherus BioSciences' stock price today?

One share of CHRS stock can currently be purchased for approximately $17.86.

How much money does Coherus BioSciences make?

Coherus BioSciences has a market capitalization of $1.37 billion and generates $475.82 million in revenue each year. The biotechnology company earns $132.24 million in net income (profit) each year or ($3.14) on an earnings per share basis.

How many employees does Coherus BioSciences have?

Coherus BioSciences employs 317 workers across the globe.

Does Coherus BioSciences have any subsidiaries?

The following companies are subsidiares of Coherus BioSciences: Coherus Intermediate Corp, InteKrin, InteKrin Russia, and InteKrin Therapeutics Inc..

When was Coherus BioSciences founded?

Coherus BioSciences was founded in 2010.

What is Coherus BioSciences' official website?

The official website for Coherus BioSciences is www.coherus.com.

Where are Coherus BioSciences' headquarters?

Coherus BioSciences is headquartered at 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065.

How can I contact Coherus BioSciences?

Coherus BioSciences' mailing address is 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065. The biotechnology company can be reached via phone at (650) 649-3530 or via email at [email protected].